EGFR and neoplasm: Newer antibody formulations, like SYM015, which targets multiple MET epitopes, or amivantamab, which targets both the MET and EGFR pathways, are showing promise by engaging immune mechanisms that enhance tumor destruction or offering a way to address resistance mechanisms that often arise with single-target therapies.